通过过程强化提高基于细胞的疫苗制造

摘要

有许多司机能够加强疫苗的制造。SARS-COV-2的出现仅添加到它们中。自流行开始以来，我们正在看到疫苗开发和批准的加速，包括施用新型预防性疫苗方式。我们还看到了对纪念和一般性的纪律纪念的升值增加。同时，对将新的谅解和技术应用于生物制药过程的加剧期间甚至很有兴趣。这些发展的婚姻定义了疫苗制造过程强化领域。其实施中的困难包括许多不同的疫苗类型 - 从缀合物到杂交物到核酸的基于核酸。然后，存在各自和开发的制造方法，模式和平台 - 从转化细菌的发酵到重组动物细胞的生物反应器培养物中，以在转基因植物中产生病毒样颗粒。在整个生物制造领域发生进展，从过程开发（PD）技术到制造平台，材料，设备和设施。BioProcess强化是指用于每种细胞，时间，体积，足迹或成本生产更多产品的系统。 The need for vaccine manufacturing process intensification is being driven by desires for cost control, process efficiency, and the heightened pressures of pandemic response. We are seeing great interest in the power of such disciplines as synthetic biology, process simplification, continuous bioprocessing, and digital techniques in the optimization of vaccine PD and manufacturing. Other powerful disciplines here include process automation, improved monitoring, optimized culture materials, and facility design. The intent of this short commentary is to provide a brief review, and a few examples of the exciting advances in the equipment, technology and processes supporting this activity.